Abiomed (ABMD) – Business Wire
-
FDA Approves Impella ECP Pivotal Heart Pump and First Patients Enrolled in Pivotal Clinical Trial
-
Johnson & Johnson Announces Extension of Abiomed Tender Offer to December 21, 2022
-
First Patients in the World Treated with Impella RP Flex with SmartAssist
-
Abiomed Announces Second Quarter Revenue of $266 Million, up 11% in Constant Currency*, up 7% on a Reported Basis Year Over Year
-
Johnson & Johnson to Acquire Abiomed
-
Impella RP Flex with SmartAssist Receives FDA Approval to Treat Right Heart Failure
-
Abiomed Creates Patient Assistance Program to Address Disparities in Healthcare
-
MedTechVets Appoints Patrice Sutherland, Enterprise Executive Director at Integra LifeScience, as New Board Chairperson
-
Abiomed Successfully Completes All Impella Post-Approval Studies for High-Risk PCI, Cardiogenic Shock, Post-Cardiotomy Cardiogenic Shock and Right Heart Failure
-
U.S. FDA Grants 510(k) Clearance for Impella Low Profile Sheath
-
Yale University Study Demonstrates Significant Survival Benefit in High-Risk PCI with Impella Support
-
Abiomed Second Quarter Fiscal 2023 Earnings and Conference Call Notification
-
Multi-Center, Multi-Society Study of Impella-supported Patients with Cardiogenic Shock due to Myocarditis in Japan Achieves 30-day Survival of 77%
-
Large, Multi-Center, Multi-Society Study of Impella-supported Patients Finds 30-day AMI Cardiogenic Shock Survival of 81%
-
Unloading with Impella for 30 Minutes Before PCI Associated with Reduced Infarct Size in STEMI Patients
-
FDA Approves RECOVER IV Randomized Controlled Trial with Exception from Informed Consent (EFIC)
-
TCT 2022: Impella Enables Complete Revascularization, Improved Quality of Life and Native Heart Recovery
-
Restore EF Study Shows Heart Function, Symptom Improvements for High-Risk PCI Patients Supported by Impella
-
ABIOMED Announces First Quarter Record Revenue of $277 Million, up 10% Year Over Year, up 12% in Constant Currency*
-
Abiomed First Quarter Fiscal 2023 Earnings and Conference Call Notification
-
Abiomed to Host Investor Call on Heart Failure Opportunity With Impella 5.5 and Impella BTR Heart Pumps
-
Abiomed to Present (Live) at the William Blair 42nd Annual Growth Stock Conference
-
SCAI 2022 Scientific Sessions Highlight Impella Research, Advancements to Improve Cardiogenic Shock Outcomes
-
Abiomed Announces Fourth Quarter Record Revenue of $270 Million, up 12% Year Over Year
-
World’s First Patient Implanted with Impella BTR Minimally Invasive Heart Pump
-
Abiomed Fourth Quarter Fiscal 2022 Earnings and Conference Call Notification
-
First Patient in Japan Treated with Impella 5.5 with SmartAssist
-
Abiomed to Host Investor Call on Impella ECP, the World’s Smallest Heart Pump at 9 French
-
Abiomed to Present at the SVB Leerink 11th Annual Global Healthcare Conference
-
Abiomed Announces Record Revenue of $261 Million, up 13% Year Over Year
-
Abiomed Third Quarter Fiscal 2022 Earnings and Conference Call Notification
-
Early Feasibility Study Demonstrates Successful Use of Abiomed’s preCARDIA Technology
-
Regulators Approve Impella 5.5 With SmartAssist in Japan and Hong Kong; US FDA Grants Impella BTR Conditional IDE Approval for First-in-Human Early Feasibility Study
-
Abiomed to Present at the 40th Annual J.P. Morgan Healthcare Conference
-
Abiomed to Present at Upcoming Investor Conferences
-
Two Large Studies Demonstrate Complete Revascularization with Impella Heart Pumps Improves Ejection Fraction and Long-Term Patient Outcomes
-
Impella Advances to Higher Level of Recommendation in Newest ESC Guidelines
-
TCT 2021 to Highlight Improved Patient Outcomes with Impella’s Small, Smart and Connected Technology
-
Abiomed Announces Q2 FY 2022 Revenue of $248 Million, Up 18% Year Over Year
-
Abiomed Second Quarter Fiscal 2022 Earnings and Conference Call Notification
-
FDA Grants Breakthrough Device Designation to Impella ECP, the World’s Smallest Heart Pump
-
Abiomed Announces Record Revenue of $253 Million, Up 53% Year Over Year
-
Abiomed First Quarter Fiscal 2022 Earnings and Conference Call Notification
-
FDA Grants Highest Level of Approval to the Next Generation of Impella RP to Treat Right Heart Failure
-
Abiomed Acquires preCARDIA, a Breakthrough Medical Device Company, to Improve Outcomes for Heart Failure Patients
-
Abiomed to Present at Upcoming Investor Conferences
-
Abiomed Announces Record Revenue of $241 Million, up 17% Year Over Year, With 26.0% Operating Margin
-
Final Results from the National Cardiogenic Shock Initiative (NCSI) Study Demonstrate the Benefit of Early Cardiac Unloading with Impella
-
Dr. Paula A. Johnson Joins Abiomed Board of Directors
-
First Patient Enrolled in PROTECT IV Randomized Controlled Trial of Impella
Back to ABMD Stock Lookup